Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells

Kaitlyn M. Dykstra, Cheryl Allen, Ella J. Born, Huaxiang Tong, Sarah A. Holstein

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Multiple myeloma (MM) is characterized by the production of monoclonal protein (MP). We have shown previously that disruption of the isoprenoid biosynthetic pathway (IBP) causes a block in MP secretion through a disruption of Rab GTPase activity, leading to an enhanced unfolded protein response and subsequent apoptosis in MM cells. Autophagy is induced by cellular stressors including nutrient deprivation and ER stress. IBP inhibitors have been shown to have disparate effects on autophagy. Here we define the mechanisms underlying the differential effects of IBP inhibitors on autophagic flux in MM cells utilizing specific pharmacological inhibitors. We demonstrate that IBP inhibition induces a net increase in autophagy as a consequence of disruption of isoprenoid biosynthesis which is not recapitulated by direct geranylgeranyl transferase inhibition. IBP inhibitor-induced autophagy is a cellular defense mechanism as treatment with the autophagy inhibitor bafilomycin A1 enhances the cytotoxic effects of GGPP depletion, but not geranylgeranyl transferase inhibition. Immunofluorescence microscopy studies revealed that IBP inhibitors disrupt ER to Golgi trafficking of monoclonal light chain protein and that this protein is not a substrate for alternative degradative pathways such as aggresomes and autophagosomes. These studies support further development of specific GGTase II inhibitors as anti-myeloma agents.

Original languageEnglish (US)
Pages (from-to)41535-41549
Number of pages15
JournalOncotarget
Volume6
Issue number39
DOIs
StatePublished - Jan 1 2015

Fingerprint

Biosynthetic Pathways
Terpenes
Autophagy
Multiple Myeloma
Transferases
Proteins
rab GTP-Binding Proteins
Unfolded Protein Response
Fluorescence Microscopy
Pharmacology
Apoptosis
Light
Food

Keywords

  • Autophagy
  • Isoprenoid
  • Myeloma
  • Prenylation
  • RabGTPase

ASJC Scopus subject areas

  • Oncology

Cite this

Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. / Dykstra, Kaitlyn M.; Allen, Cheryl; Born, Ella J.; Tong, Huaxiang; Holstein, Sarah A.

In: Oncotarget, Vol. 6, No. 39, 01.01.2015, p. 41535-41549.

Research output: Contribution to journalArticle

Dykstra, Kaitlyn M. ; Allen, Cheryl ; Born, Ella J. ; Tong, Huaxiang ; Holstein, Sarah A. / Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. In: Oncotarget. 2015 ; Vol. 6, No. 39. pp. 41535-41549.
@article{a6530f680a484e43956d79152bc9b941,
title = "Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells",
abstract = "Multiple myeloma (MM) is characterized by the production of monoclonal protein (MP). We have shown previously that disruption of the isoprenoid biosynthetic pathway (IBP) causes a block in MP secretion through a disruption of Rab GTPase activity, leading to an enhanced unfolded protein response and subsequent apoptosis in MM cells. Autophagy is induced by cellular stressors including nutrient deprivation and ER stress. IBP inhibitors have been shown to have disparate effects on autophagy. Here we define the mechanisms underlying the differential effects of IBP inhibitors on autophagic flux in MM cells utilizing specific pharmacological inhibitors. We demonstrate that IBP inhibition induces a net increase in autophagy as a consequence of disruption of isoprenoid biosynthesis which is not recapitulated by direct geranylgeranyl transferase inhibition. IBP inhibitor-induced autophagy is a cellular defense mechanism as treatment with the autophagy inhibitor bafilomycin A1 enhances the cytotoxic effects of GGPP depletion, but not geranylgeranyl transferase inhibition. Immunofluorescence microscopy studies revealed that IBP inhibitors disrupt ER to Golgi trafficking of monoclonal light chain protein and that this protein is not a substrate for alternative degradative pathways such as aggresomes and autophagosomes. These studies support further development of specific GGTase II inhibitors as anti-myeloma agents.",
keywords = "Autophagy, Isoprenoid, Myeloma, Prenylation, RabGTPase",
author = "Dykstra, {Kaitlyn M.} and Cheryl Allen and Born, {Ella J.} and Huaxiang Tong and Holstein, {Sarah A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.6365",
language = "English (US)",
volume = "6",
pages = "41535--41549",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "39",

}

TY - JOUR

T1 - Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells

AU - Dykstra, Kaitlyn M.

AU - Allen, Cheryl

AU - Born, Ella J.

AU - Tong, Huaxiang

AU - Holstein, Sarah A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Multiple myeloma (MM) is characterized by the production of monoclonal protein (MP). We have shown previously that disruption of the isoprenoid biosynthetic pathway (IBP) causes a block in MP secretion through a disruption of Rab GTPase activity, leading to an enhanced unfolded protein response and subsequent apoptosis in MM cells. Autophagy is induced by cellular stressors including nutrient deprivation and ER stress. IBP inhibitors have been shown to have disparate effects on autophagy. Here we define the mechanisms underlying the differential effects of IBP inhibitors on autophagic flux in MM cells utilizing specific pharmacological inhibitors. We demonstrate that IBP inhibition induces a net increase in autophagy as a consequence of disruption of isoprenoid biosynthesis which is not recapitulated by direct geranylgeranyl transferase inhibition. IBP inhibitor-induced autophagy is a cellular defense mechanism as treatment with the autophagy inhibitor bafilomycin A1 enhances the cytotoxic effects of GGPP depletion, but not geranylgeranyl transferase inhibition. Immunofluorescence microscopy studies revealed that IBP inhibitors disrupt ER to Golgi trafficking of monoclonal light chain protein and that this protein is not a substrate for alternative degradative pathways such as aggresomes and autophagosomes. These studies support further development of specific GGTase II inhibitors as anti-myeloma agents.

AB - Multiple myeloma (MM) is characterized by the production of monoclonal protein (MP). We have shown previously that disruption of the isoprenoid biosynthetic pathway (IBP) causes a block in MP secretion through a disruption of Rab GTPase activity, leading to an enhanced unfolded protein response and subsequent apoptosis in MM cells. Autophagy is induced by cellular stressors including nutrient deprivation and ER stress. IBP inhibitors have been shown to have disparate effects on autophagy. Here we define the mechanisms underlying the differential effects of IBP inhibitors on autophagic flux in MM cells utilizing specific pharmacological inhibitors. We demonstrate that IBP inhibition induces a net increase in autophagy as a consequence of disruption of isoprenoid biosynthesis which is not recapitulated by direct geranylgeranyl transferase inhibition. IBP inhibitor-induced autophagy is a cellular defense mechanism as treatment with the autophagy inhibitor bafilomycin A1 enhances the cytotoxic effects of GGPP depletion, but not geranylgeranyl transferase inhibition. Immunofluorescence microscopy studies revealed that IBP inhibitors disrupt ER to Golgi trafficking of monoclonal light chain protein and that this protein is not a substrate for alternative degradative pathways such as aggresomes and autophagosomes. These studies support further development of specific GGTase II inhibitors as anti-myeloma agents.

KW - Autophagy

KW - Isoprenoid

KW - Myeloma

KW - Prenylation

KW - RabGTPase

UR - http://www.scopus.com/inward/record.url?scp=84951841773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951841773&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6365

DO - 10.18632/oncotarget.6365

M3 - Article

C2 - 26595805

AN - SCOPUS:84951841773

VL - 6

SP - 41535

EP - 41549

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -